Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study ; day:15 ; month:10 ; year:2018 ; pages:1-9
Breast cancer ; (15.10.2018), 1-9
- Urheber
-
Tsurutani, Junji
- Beteiligte Personen und Organisationen
-
Sakata, Yukinori
Matsuoka, Toshiyuki
SpringerLink (Online service)
- DOI
-
10.1007/s12282-018-0919-8
- URN
-
urn:nbn:de:101:1-2018112020041934074538
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsurutani, Junji
- Sakata, Yukinori
- Matsuoka, Toshiyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Informative gene network for chemotherapy-induced peripheral neuropathy
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Chemotherapy-induced peripheral neuropathy biomarkers: current updates, challenges, and potentials
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control
Eribulin drug review
Type of exercise may influence postural adaptations in chemotherapy‐induced peripheral neuropathy
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
Modulation of tissue specific membrane transporters for prevention of chemotherapy-induced peripheral neuropathy
Informative gene network for chemotherapy-induced peripheral neuropathy
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Chemotherapy-induced peripheral neuropathy biomarkers: current updates, challenges, and potentials
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control
Eribulin drug review
Type of exercise may influence postural adaptations in chemotherapy‐induced peripheral neuropathy
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
Modulation of tissue specific membrane transporters for prevention of chemotherapy-induced peripheral neuropathy
Informative gene network for chemotherapy-induced peripheral neuropathy
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Chemotherapy-induced peripheral neuropathy biomarkers: current updates, challenges, and potentials
Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control
Eribulin drug review
Type of exercise may influence postural adaptations in chemotherapy‐induced peripheral neuropathy
Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study